We conducted a retrospective analysis to evaluate the role of frontline ICIs in advanced BRAF-mutant NSCLC compared to anti-BRAF/MEK agents and chemotherapy, hoping to assist in clinical decision-making and optimize treatment strategies for these patients. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.